TICKERNERD
Menu
CHRSCHRSHealthcare · Biotechnology

CHRS Stock Forecast: Coherus Oncology, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$0.90
−22.55% on the day

The 6 Wall Street analysts covering Coherus Oncology, Inc. hold a median 12-month price target of $8.5 — +846.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 29 Oct 2026 — in the lower half.

Market cap
$138.7M
Ticker Nerd rank
48/ 100
Median analyst target
$8.50
Analysts covering
6
Revenue$14.3M+39.5% y/y
Operating income−$32.3M
Net income−$20.6M
Free cash flow−$62.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.4%
1M
−23.9%
YTD
−36.7%
1Y
−48.1%
From 52W high
−64.2%
From 52W low
0.0%
$0.90
$2.51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CHRS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Coherus Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Oct 2026
48/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
71
Volatility
67
Revisions
67
Quality
58
Accruals
46
Growth
46
Value
45
Momentum
31
Issuance
28

Size (71): Smaller than most of the companies we track.

Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CHRS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CHRS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26CHRSHigh $10.00Median $8.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $4.00Median $8.50High $10.00

The green dot is the last close — the median target sits +846.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Oct 2026HC Wainwright & Co.AssumesBuy$7.00
7 Aug 2026GuggenheimMaintainsBuy$12 → $10
11 May 2026GuggenheimInitiatesBuy—
22 Jan 2026OppenheimerInitiatesOutperform—
4 Sept 2025Maxim GroupUpgradeBuy—
29 Apr 2025HC Wainwright & Co.ReiteratesBuy—
24 Apr 2025UBSMaintainsNeutral—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
23 Jan 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—
5 Dec 2024BairdMaintainsOutperform—
4 Dec 2024HC Wainwright & Co.ReiteratesBuy—
8 Nov 2024BairdMaintainsOutperform—
7 Nov 2024HC Wainwright & Co.ReiteratesBuy—
16 Sept 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024UBSDowngradeNeutral—
5 Aug 2024HC Wainwright & Co.ReiteratesBuy—
1 July 2024BairdMaintainsOutperform—
24 May 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024Truist SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CHRS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CHRS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Coherus Oncology, Inc. returned −48.1% against +13.1% for the S&P 500, dividends included.

CHRS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26CHRSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CHRS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Coherus Oncology, Inc. (CHRS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.1×

Cheaper than 68% of US stocks

Price / sales
2.7×

Cheaper than 43% of US stocks

Price / book
2.3×

Cheaper than 39% of US stocks

EV / EBITDA
−0.6×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
39.5%

Higher than 83% of US stocks

Earnings growth (YoY)
39.5%

Higher than 71% of US stocks

Gross margin
70.4%

Higher than 83% of US stocks

Operating margin
−226.0%

Higher than 10% of US stocks

Net margin
−259.4%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−178.4%

Higher than 8% of US stocks

Return on assets
−30.5%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Coherus Oncology, Inc. (CHRS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Coherus Oncology, Inc. has a market value of $138.7M and an enterprise value of $87.7M.

  • Revenue in the twelve months to 30 June 2026: $50.9M. The latest quarter grew 39.5% year on year.

  • Net income over the same four quarters: −$132.1M, a −259.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.03.

  • Free cash flow in the twelve months to 30 June 2026: −$186.0M.

  • Shares outstanding: 154.5M.

  • Trailing P/E: 3.1×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Coherus Oncology, Inc. employs 144 people — $354K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

CHRS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CHRSCoherus Oncology, Inc.$138.7M48
SPRBSpruce Biosciences, Inc.$134.6M28
CMPXCompass Therapeutics, Inc.$136.2M31
CDXSCodexis, Inc.$131.2M63
MENSJyong Biotech Ltd.$139.6M3
HUMAHumacyte, Inc.$126.7M17
HURATuHURA Biosciences, Inc.$125.1M16

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Coherus Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CHRS news & analysis

Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer Transcript

Seeking Alpha · 29 Oct 2026neutral

The headline identifies a Seeking Alpha transcript discussing Coherus Oncology’s interim clinical data for tagmokitug in esophageal cancer; no specific data or outcomes are provided in the supplied excerpt.

Why it matters — CHRS watchers may find the discussion relevant to the company’s tagmokitug clinical program, though the excerpt contains no details on the results.

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

MarketBeat · 29 Oct 2026positive

Coherus Oncology presented interim data for investigational tagmokitug across several solid-tumor settings, highlighting early activity in esophageal squamous cell carcinoma (ESCC). The company said it plans to expand cohorts and discuss potential regulatory paths with the FDA.

Why it matters — CHRS watchers may track the early ESCC findings and the planned cohort expansion and FDA discussions as the program develops.

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

GlobeNewsWire · 28 Oct 2026positive

Coherus Oncology reported interim tagmokitug data from its TREGCHECK program, including a confirmed 75% ORR in evaluable first-line ESCC patients regardless of PD-L1 status and 100% among PD-L1-positive patients. The company also reported durable clinical benefit in second-line ESCC, activity across five indications, and a manageable safety profile, and outlined a path to advance development.

Why it matters — The interim results and continued-development plans provide CHRS watchers an update on the progress and observed clinical activity of its investigational tagmokitug program.

Coherus to Participate in Upcoming Investor Conferences

GlobeNewsWire · 27 Oct 2026neutral

Coherus Oncology announced that it will webcast its participation in upcoming investor conferences.

Why it matters — CHRS watchers can look for the company’s conference participation via webcast.

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

GlobeNewsWire · 26 Oct 2026neutral

Coherus Oncology announced that it will release its third-quarter 2026 financial results on November 9, 2026. Management will host a conference call and webcast at 5:00 p.m. Eastern Daylight Time to discuss the results and provide a general business update.

Why it matters — CHRS watchers can hear the company’s quarterly results and business update during the scheduled call and webcast.

FAQ

Frequently asked questions about CHRS stock

What is the CHRS stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Coherus Oncology, Inc. have a median 12-month price target of $8.5, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CHRS stock a buy right now?

Of the 6 analysts covering Coherus Oncology, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Coherus Oncology, Inc. 48 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CHRS?

As at 29 Oct 2026, Coherus Oncology, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (71 of 100).

Will CHRS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +846.1% from the last close, and Ticker Nerd's factor model ranks Coherus Oncology, Inc. 48 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CHRS stock forecast for 2030?

No analyst covering Coherus Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CHRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has CHRS stock performed over the past year?

Coherus Oncology, Inc. returned -48.1% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Coherus Oncology, Inc. do?

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer.

What is the latest news on CHRS?

The most recent item we track (Seeking Alpha, 29 Oct 2026): "Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer Transcript". The headline identifies a Seeking Alpha transcript discussing Coherus Oncology’s interim clinical data for tagmokitug in esophageal cancer; no specific data or outcomes are provided in the supplied excerpt.

Company

About Coherus Oncology, Inc.

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer. The company’s current portfolio centers on LOQTORZI, an approved PD-1 inhibitor used in oncology treatment, alongside additional clinical-stage candidates designed to address several solid tumors and tumor types. Coherus Oncology works across research, regulatory development, manufacturing, and commercialization, with an emphasis on combination therapies that may expand the use of its cancer medicines. Its business is concentrated on oncology therapeutics, reflecting a focused role in the cancer drug market and a strategy built around antibody-based and immune-based treatments. Based in Redwood City, California, Coherus Oncology serves as a specialized player in the U.S. biopharmaceutical sector, with its commercial activities and pipeline development aimed at improving treatment options in modern oncology.

CEO Mr. Dennis M. Lanfear · 144 employees · United States · https://www.coherus.com